HomeAI · summaries
Storia in 11 fonti
AstraZeneca se suma al mercado contra la obesidad, nueva pastilla da resultados alentadores en ensayo clínico
Especialistas consideran que el medicamento merece evaluaciones más amplias antes de solicitar su autorización
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
- ·
endpoints.news
AstraZeneca's obesity pill matches rivals in Phase 2, anchoring $5B franchise push
AstraZeneca's oral GLP-1 elecoglipron cut weight up to 10.5% in Phase 2, as AZ launches multiple Phase 3 trials targeting a $5B obesity franchise.
